Why PepGen Inc.’s (PEPG) Stock Is Up 6.47%
As of Friday, November 06, PepGen Inc.’s PEPG share price has surged by 6.47%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Commentary & Analysis
Why PepGen Inc.’s (PEPG) Stock Is Up 9.35%
As of Wednesday, November 04, PepGen Inc.’s PEPG share price has surged by 9.35%, which has investors questioning if this is right time to sell.Jenna Brashear
Why PepGen Inc.’s (PEPG) Stock Is Down 7.26%
As of Friday, October 30, PepGen Inc.’s PEPG share price has dipped by 7.26%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why PepGen Inc.’s (PEPG) Stock Is Down 5.56%
As of Friday, October 23, PepGen Inc.’s PEPG share price has dipped by 5.56%, which has investors questioning if this is right time to buy.Michael Rose
Why PepGen Inc.’s (PEPG) Stock Is Up 8.52%
As of Tuesday, October 20, PepGen Inc.’s PEPG share price has surged by 8.52%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $171.1 | $219.9 | 27% |
|
| Shares Out (Mil) | 69.2 | 54.1 | 55% |
|
| Institutional Ownership | 99.4% | 92.9% | 88% |
|
| Float (Mil) | 36.1 | 41.4 | 39% |
|
| Beta | 2.01 | 0.95 | 92% |
|
| Avg Daily Volume (000s) | 983 | 522 | 68% |
|
| Price Change (52-week) |
(45.6%) | 44.7% | 22% |
|
| Growth | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (116.2%) | (10.1%) | 1% |
|
| EPS (5yr) | 14.7% | 15.8% | 56 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (48.6%) | (15.7%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.273) | ($1.100) | ($1.060) | |
| Month Ago EPS | ($0.267) | ($1.072) | ($1.037) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.267) | ($1.072) | ($1.037) | |
| Year/Year Chg | 6.2% | (48.2%) | (48.7%) | |
| Financials | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($72) | ($44) | 13% |
|
| EPS (TTM) | ($1.190) | ($1.500) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($35) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($12) | $0 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $73 | $166 | 19% |
|
| Valuation | PEPG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.43 | 2.06 | 42% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (59.1%) | (47.5%) | 10% |
|
| ROE | (75.5%) | (52.7%) | 11% |
|
| Liabilities to Assets | 15.5% | 29.6% | 10% |
|
| F-Score | 3 | 3 | 18% |
|
PepGen Inc. did not pass any screens on 11/6/2026.
